Myocardial and pericardial disease in HIV

Current Treatment Options in Cardiovascular Medicine

Volumn 4, Issue 6, 2002, Pages 497-509

  Harmon, William G ^a   Dadlani, Gul H ^a   Fisher, Stacy D ^a   Lipshultz, Steven E ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Colesevelam; Main Drug Interaction; Pericardial Effusion; Rescriptor; Ritonavir

Indexed keywords

EID: 2442420099     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-002-0043-z     Document Type: Article

References (27)

1. Yunis NA, Stone VE: Cardiac manifestations of HIV/ AIDS: a review of disease spectrum and clinical management. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18:145–154.
2. Rickerts V, Brodt H, Staszewski S, et al.: Incidence of myocardial infarction in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 2000, 5:329–333.
3. Aoun S, Ramos E: Hypertension in the HIV-infected patient. Curr Hypertens Rep 2000, 2:478–481.
4. Serrano-Heranz R, Camino A, Vilacosta I, et al.: Tuberculous cardiac tamponade and AIDS. Eur Heart J 1995, 16:430–432.
5. Barbaro G, Fisher SD, Lipshultz SE: Pathogenesis of HIV-associated cardiovascular complications. Lancet Infect Dis 2001, 1:115–124.
6. Starc TJ, Lipshultz SSE, Kaplan S, et al.: Cardiac complications in children with human immunodeficiency virus infection. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group, National Heart, Lung, and Blood Institute. Pediatrics 1999, 104:e14. (HIV, cardiac disease, pediatrics).http://www.pediatrics.org/cgi/content/full/104/2/e14
7. Bowels NE, Kearney DL, JA, Towbin et al.: The detection of viral genomes by polymerase chain reaction in the myocardium of pediatric patients with advanced HIV disease. J Am Coll Cardiol 1999, 34:857–865.
8. Lipshultz SE, Easley KA, Orav EJ, et al.: Cardiac dysfunction and mortality in HIV-infected children: the Prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 2000, 102:1542–1548.
9. Dolin R, Masur H, Saag MS: Cardiac disease. In AIDS Therapy. Edited by Dolin R et al. Philadelphia, PA:Churchill Livingstone; 2002:680–698.
10. Dube MP, Sprecher D, Henry WK, et al.: Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendation of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000, 31:11216–11224. Reviews current knowledge and initial dyslipidemia treatment recommendations.
11. Danner SA, Carr A, Leonard JM, et al.: A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995, 333:1528–1533.
12. Mooser V, Carr A: Antiretroviral therapy-associated hyperlipidemia in HIV Disease. Curr Opin Lipidol 2001, 12:313–319.
13. Freeman R, Roberts MS, Friedman LS, Broadbridge C: Autonomic function and human immunodeficiency virus infection. Neurology 1990, 40:575–580.
14. Kocheril A, Bokhari SA, Batsford WP, Sinusas AJ: Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin Electrophysiol 1995, 20:2810–2816.
15. Moorthy LN, Lipshultz SE: Cardiovascular monitoring of HIV-infected patients. In Cardiology in AIDS. Edited by Lipshultz SE. New York, NY: Chapman and Hall;1998:345–386.
16. Heidenreich PA, Eisenberg MJ, Kee LL, et al.: Pericardial effusion in AIDS. Incidence and survival. Circulation 1995, 92:3229–3234.
17. Etok L, Wallach F: Cardiac tamponade in a patient with AIDS: a review of pericardial disease in patients with HIV infection. Mt Sinai J Med 1998, 65:33–39.
18. Lederman R, Cheitlin M: Pericardial disease in HIV infection. In Cardiology in AIDS. Edited by Lipshultz SE.New York, NY: Chapman and Hall; 1998:195–208.
19. Heart Failure Guideline Panel: Heart Failure: Evaluation and Care of Patients with Left Ventricular Systolic Dysfunction. Clinical Practice Guideline No. 11. AHCPR Publication 94:6012. Rockville, MD: U.S. Dept. of Health and Human Services, Agency for Health Care Policy and Research; 1994.
20. Hunt SA, Baker DW, Chin MH, et al.: ACC/AHA guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult. Executive Summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation 2001, 104:2996–3007. Outlines current standards of care for patients with or at risk for developing heart failure.
21. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcome Prevention Evaluation Study Investigators [no authors listed]. Engl J Med 2000, 342:145–153.
22. ICROMEDEX Healthcare Series, vol 109. http://eg.miner.rochester.edu/mdx112/mdxcgi/ mdxhtml.exe?&tmpl=mdxhome.tm1&SCRNAME=mdxhome&CTL=/bigovid/mdx112/mdxcgi/megat.sys.Accessed April 10, 2002.
23. Drug Topic Red Book. Montvale, NJ: Medical Economics Co.; 2001.
24. Currie PF, Goldman JH, Caforio AL, et al.: Cardiac autoimmunity in HIV related heart muscle disease. Heart 1998, 79:599–604.
25. Lipshultz SE, Orav EJ, Sanders SP, Colan SD: Immunoglobulins and left ventricular structure and function in pediatric HIV infection. Circulation 1995, 92:2220–2225.
26. Lipshultz SE, Fisher SD, Lai WW, Miller TL: Cardiovascular monitoring and therapy for HIV-infected patients. Ann N Y Acad Sci 2001, 946:236–273. A comprehensive review of cardiovascular assessment and treatment of HIV-infected patients.
27. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486–2497.